Top Clinical Trials companies in Australia by Debt to Equity Ratio

This ranking features the top 10 Clinical Trials companies in Australia ranked by Debt to Equity Ratio, averaging a Debt to Equity Ratio of 0.37, for February 06, 2025.
#
Name
Debt to Equity Ratio
Reported Date
Stock Price
Change
Price (30 days) Country
1
1.74
June 30, 2024 USD 2.33 0.08%

Australia

2
0.70
June 30, 2024 USD 169.95 -0.56%

Australia

3
0.56
June 30, 2024 USD 0.74 0.62%

Australia

4
0.25
June 30, 2024 USD 1.90 -4.74%

Australia

5
0.21
June 30, 2024 USD 1.23 -0.40%

Australia

6
0.12
Dec. 31, 2023 USD 18.33 -0.84%

Australia

7
0.08
Dec. 31, 2023 USD 6.16 2.82%

Australia

8
0.02
June 30, 2024 USD 0.74 1.48%

Australia

9
0.01
June 30, 2024 USD 2.09 0.97%

Australia

10
0.00
June 30, 2024 USD 7.27 0.71%

Australia

Frequently Asked Questions
  • Which Clinical Trials company in Australia has the highest Debt to Equity Ratio ?

    The Clinical Trials company in Australia with the highest Debt to Equity Ratio is Australian Clinical Labs Limited (ASX: ACL.AX) at 1.74.

  • Which Clinical Trials company in Australia has the lowest Debt to Equity Ratio ?

    The Clinical Trials company in Australia with the lowest Debt to Equity Ratio is Clinuvel Pharmaceuticals Limited (ASX: CUV.AX) at 0.00.

SV Wall Street